Psychiatric Clinics of North America
March 1, 2026
Aaron Keshen, Stephen Touyz, Emilie Lacroix et al.
This article explores innovative pharmacologic treatments for eating disorders, focusing on psychedelics, stimulant medications, and other emerging therapies. Preliminary evidence for psychedelics (eg, psilocybin) highlight their potential to enhance cognitive flexibility and support psychological interventions in some eating disorders (eg, anorexia nervosa). Stimulants like lisdexamfetamine...
Psychiatric Clinics of North America
September 1, 2025
Eric M. J. Morris, Daniel D Simsion
5 citations
Acceptance and commitment therapy (ACT) is a third-wave cognitive-behavioral therapy, which focuses on acceptance, mindfulness, and values-based actions to support living a rich and meaningful life. ACT has been successfully applied to support recovery from psychosis across multiple contexts. This article provides an overview of ACT for psychosis, followed by an outline of how to effectively...
Psychiatric Clinics of North America
October 9, 2024
Mindfulness-based interventions have demonstrated efficacy for a wide range of clinical concerns and populations. Mindfulness-based Intervention for Tics (MBIT) is a recently developed brief, online group intervention for adults with tics. Preliminary evidence suggests that MBIT is feasible, acceptable, and safe. Symptomatic improvements compare favorably with those associated with...
Psychiatric Clinics of North America
June 1, 2024
Lewis Leone, Bryan McSpadden, Annamarie Demarco et al.
Administration of psychedelics for mental health treatment, typically referred to as "psychedelic-assisted therapy," is a broad term with a very heterogeneous implementation. Despite increasing interest in the clinical application of psychedelic compounds for psychiatric disorders, there is no consensus on how to best integrate the psychedelic experience with evidence-based psychotherapeutic...
Psychiatric Clinics of North America
June 1, 2023
Shubham Kamal, Manish Kumar Jha, Rajiv Radhakrishnan
32 citations
There is increasing interest in exploring the therapeutic potential of psychedelics in treatment-resistant depression (TRD). Classic psychedelics (such as psilocybin, LSD, ayahuasca/DMT), and atypical psychedelics (such as ketamine) have been studied in TRD. The evidence for the classic psychedelics TRD is limited at the present time; early studies however show promising results. There is also...
Psychiatric Clinics of North America
June 2023
Anna Feeney, George I. Papakostas
Ketamine and esketamine have rapid-onset antidepressant effects and may be considered for the management of treatment-resistant depression. Intranasal esketamine has regulatory approval in the United States and European Union. Intravenous ketamine is often administered off-label as an antidepressant, though no standard operating procedures exist. Repeated administrations and the use of a...
Psychiatric Clinics of North America
September 18, 2017
Stefan G Hofmann, Angelina F Gómez
Synopsis This article reviews the ways in which cognitive and behavioral treatments for depression and anxiety have been advanced by the application of mindfulness practices. Research on mindfulness-based interventions (MBIs) has increased exponentially in the past decade. The most common include Mindfulness-Based Stress Reduction (MBSR) and Mindfulness-Based Cognitive Therapy (MBCT). MBIs have...
Psychiatric Clinics of North America
June 1, 2012
Stephen Ross
54 citations
Only time will tell if serotonergic hallucinogen-assisted psychotherapy treatment paradigms for SUDs will prove to be safe and effective in double-blind, placebo-controlled clinical trials. If they are, they would truly constitute a novel psychopharmacologic-psychosocial treatment paradigm to treat addictive disorders, although the risk of adverse psychological events would have to be...
Psychiatric Clinics of North America
September 1, 2010
Stefan G Hofmann, Alice T. Sawyer, Angela Fang
This article reviews the current state of empirical research on the purported "new wave" of cognitive behavioral therapy (CBT). A particular emphasis is given to mindfulness-based treatments and acceptance and commitment therapy (ACT). Mindfulness-based approaches and ACT are evaluated with regard to their efficacy and comparison with traditional CBT. Deviations from CBT are explained within...
Psychiatric Clinics of North America
December 1, 1984
S Cohen
The hallucinogenic drugs represent a recurrent outbreak pattern with each generation or two seeming to rediscover their ego-dissolving effects. The inhalants produce a short-lived intoxication with certain volatile solvents affecting specific organ systems.